(Q37342445)

19 August 2017

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

0 references

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research (English)

1 reference

disease-modifying antirheumatic drug

19 August 2017

0 references

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

1 reference

14 November 2020

1 reference

C Salliot

1

1 reference

19 August 2017

D van der Heijde

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

5 December 2008

1 reference

Annals of the Rheumatic Diseases

19 August 2017

1 July 2009

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

5 references

19 August 2017

13 March 2019

17 June 2019

30 June 2019

14 November 2020

68

1 reference

19 August 2017

1100-1104

1 reference

19 August 2017

7

1 reference

Creative Commons Attribution-NonCommercial

19 August 2017

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

on focus list of Wikimedia project

ScienceSource

0 references

cites work

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

The relative toxicity of disease-modifying antirheumatic drugs

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Methotrexate therapy in rheumatoid arthritis: 15 years experience.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

A toxicity index for comparison of side effects among different drugs

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689525

Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients

20 October 2018

1 reference

12 December 2020

Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety

1 reference

12 December 2020

A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy

1 reference

12 December 2020

Long-term experience with low dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis

1 reference

12 December 2020

Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years

1 reference

12 December 2020

Long-term treatment of destructive rheumatoid arthritis with methotrexate

1 reference

12 December 2020

Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy

1 reference

12 December 2020

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

12 December 2020

The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis

1 reference

12 December 2020

Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis

1 reference

12 December 2020

Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis

1 reference

12 December 2020

Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IOR

1 reference

12 December 2020

Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2008.093690

1 reference

19 August 2017

1 reference

19 August 2017

1 reference